浙江医学
浙江醫學
절강의학
ZHEJIANG MEDICAL JOURNAL
2014年
20期
1696-1698
,共3页
姜国伟%臧敏%何绿苑%蔡岗丽%陈秀华%朱颖%吴冠仪
薑國偉%臧敏%何綠苑%蔡崗麗%陳秀華%硃穎%吳冠儀
강국위%장민%하록원%채강려%진수화%주영%오관의
卡介苗素%慢性阻塞性肺疾病%干扰素-γ%白细胞介素4
卡介苗素%慢性阻塞性肺疾病%榦擾素-γ%白細胞介素4
잡개묘소%만성조새성폐질병%간우소-γ%백세포개소4
BCG- PSN%Chronic obstructive pulmonary disease%Interferon- γ%Interleukin 4
目的:探讨卡介苗素治疗对慢性阻塞性肺疾病(COPD)患者细胞免疫功能的调节作用及其意义。方法将60例COPD患者随机分为实验组和对照组各30例,对照组接受常规治疗,实验组在常规治疗基础上予卡介苗素0.35mg肌肉注射,隔日1次,共3个月。两组患者均随访6个月,观察COPD复发率及控制感染时间,检测两组患者0、3、6个月时血清中IFN-γ及IL-4水平及0、6个月时肺功能。结果0个月时两组患者细胞因子水平及肺功能的差异均无统计学意义(均P>0.05)。3个月时实验组IFN-γ水平高于对照组,IL-4水平低于对照组,差异均无统计学意义(均P>0.05),IFN-γ/IL-4比值高于对照组,差异有统计学意义(P<0.05)。6个月时实验组IFN-γ水平高于对照组,差异无统计学意义(P>0.05),IL-4水平低于对照组,差异有统计学意义(P<0.05),IFN-γ/IL-4比值及FEV1占预计值高于对照组,差异均有统计学意义(P<0.05或0.01)。随访6个月内实验组COPD复发率及控制感染时间均少于对照组,差异均有统计学意义(均P=0.020)。结论卡介苗素能增强COPD患者细胞免疫功能,改善其预后。
目的:探討卡介苗素治療對慢性阻塞性肺疾病(COPD)患者細胞免疫功能的調節作用及其意義。方法將60例COPD患者隨機分為實驗組和對照組各30例,對照組接受常規治療,實驗組在常規治療基礎上予卡介苗素0.35mg肌肉註射,隔日1次,共3箇月。兩組患者均隨訪6箇月,觀察COPD複髮率及控製感染時間,檢測兩組患者0、3、6箇月時血清中IFN-γ及IL-4水平及0、6箇月時肺功能。結果0箇月時兩組患者細胞因子水平及肺功能的差異均無統計學意義(均P>0.05)。3箇月時實驗組IFN-γ水平高于對照組,IL-4水平低于對照組,差異均無統計學意義(均P>0.05),IFN-γ/IL-4比值高于對照組,差異有統計學意義(P<0.05)。6箇月時實驗組IFN-γ水平高于對照組,差異無統計學意義(P>0.05),IL-4水平低于對照組,差異有統計學意義(P<0.05),IFN-γ/IL-4比值及FEV1佔預計值高于對照組,差異均有統計學意義(P<0.05或0.01)。隨訪6箇月內實驗組COPD複髮率及控製感染時間均少于對照組,差異均有統計學意義(均P=0.020)。結論卡介苗素能增彊COPD患者細胞免疫功能,改善其預後。
목적:탐토잡개묘소치료대만성조새성폐질병(COPD)환자세포면역공능적조절작용급기의의。방법장60례COPD환자수궤분위실험조화대조조각30례,대조조접수상규치료,실험조재상규치료기출상여잡개묘소0.35mg기육주사,격일1차,공3개월。량조환자균수방6개월,관찰COPD복발솔급공제감염시간,검측량조환자0、3、6개월시혈청중IFN-γ급IL-4수평급0、6개월시폐공능。결과0개월시량조환자세포인자수평급폐공능적차이균무통계학의의(균P>0.05)。3개월시실험조IFN-γ수평고우대조조,IL-4수평저우대조조,차이균무통계학의의(균P>0.05),IFN-γ/IL-4비치고우대조조,차이유통계학의의(P<0.05)。6개월시실험조IFN-γ수평고우대조조,차이무통계학의의(P>0.05),IL-4수평저우대조조,차이유통계학의의(P<0.05),IFN-γ/IL-4비치급FEV1점예계치고우대조조,차이균유통계학의의(P<0.05혹0.01)。수방6개월내실험조COPD복발솔급공제감염시간균소우대조조,차이균유통계학의의(균P=0.020)。결론잡개묘소능증강COPD환자세포면역공능,개선기예후。
Objective To investigate the immunoregulatory activity of BCG- PSN in patients with chronic obstructive pul-monary disease (COPD). Methods Sixty COPD patients were randomly assigned to BCG group and control group with 30 in each. Conventional treatment was given to both groups, patients in BCG group also received BCG- PSN 0.35mg i.m, q.o.d for 3 months. Both groups were fol owed up for 6 months. The recurrence rate of COPD, the time of infection control were observed in two groups. Serum levels of IFN- γ, IL- 4 at 0, 3, 6 months after treatment were measured and lung function at 0, 6 months af-ter treatment was examined. Results There were no differences in cytokines levels and lung function before treatment between two groups (P>0.05). There was also no difference in serum IFN- γand IL- 4 levels 3 months after treatment (P>0.05), but the IFN- γ/IL- 4 ratio in BCG group was higher than that in control group (P<0.05). On 6 months after treatment, serum IL- 4 levels were lower in BCG group (P<0.05), there was no difference in IFN- γlevels between two groups (P>0.05);however, the IFN- γ/IL- 4 ratio in BCG group was higher than that in control group (P<0.05), and percentage of FEV1/predicted was higher(P<0.01). The recurrence rate of COPD was lower and the time of infection control was shorter in BCG group than those in control group (P<0.05). Conclusion BCG- PSN can enhance cellular immune function and improve the prognosis of pa-tients with COPD.